Brain IORT
Brain Tumor Treatment with Xoft IORT

Challenge:
Glioblastoma (GBM) is the most common and aggressive type of malignant primary brain tumor, with a median survival of less than a year. What can we do to improve patient outcomes?1, 2

Solution:
Brain IntraOperative Radiation Therapy (IORT)* can lead to improved quality of life and preliminary results suggest extended survival for patients with this grave prognosis.

Join a new international GBM expert group:
Collaborate with GBM thought leaders from around the world. Xoft will provide a program tailored to your facility. Working together we can explore a better standard of care for GBM. For more information email us at: brainiort@xoftinc.com.

“The Xoft System is FDA-cleared, CE marked commercially available worldwide

“Xoft Brain IORT can provide targeted high dose radiation directly to the tumor bed in as little as 10 minutes in the operating room at the time of resection”
Supporting Clinical Research

The Xoft System is currently being studied for the treatment of multiple types of brain tumors in leading institutions worldwide. Investigators at the European Medical Center (EMC) in Moscow, one of the largest private medical clinics in Russia and an international leader in comprehensive care and oncology, are researching Xoft brain IORT for the treatment of recurrent glioblastoma multiforme (GBM).

Median overall survival (OS) after initial diagnosis in the IORT group was 24 months; OS for the EBRT group was 21 months. Currently, five patients were still alive from the IORT group, whereas none of the patients from the EBRT group survived. ¹

For more information email us at: brainiort@xoftinc.com.

References: